TNFRSF11B and type 2 diabetes mellitus: Therefore, this study aims to evaluate whether six bone markers (osteocalcin, osteopontin, osteonectin, osteoprotegerin, alkaline phosphatase, sclerostin) are associated with CVD risk in patients with type 2 diabetes.